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Abstract
Background: Premature birth is considered one of the main problems in modern Obstetrics. It causes more than
50 % of neonatal mortality; it is responsible for a large proportion of infant morbidity and incurs very high
economic costs. Cervical length, which can be accurately measured by ultrasound, has an inverse relationship with
the risk of preterm birth. As a result, having an effective intervention for asymptomatic patients with short cervix
could reduce the prematurity. Although recently published data demonstrates the effectiveness of vaginal
progesterone and cervical pessary, these treatments have never been compared to one another.
Methods/Design: The PESAPRO study is a noncommercial, multicenter, open-label, randomized clinical trial (RCT)
in pregnant women with a short cervix as identified by transvaginal ultrasonography at 19 to 22 weeks of
gestation. Patients are randomized (1:1) to either daily vaginal progesterone or cervical pessary until the 37th week
of gestation or delivery; whichever comes first. During the trial, women visit every 4 weeks for routine questions
and tests. The primary outcome is the proportion of spontaneous preterm deliveries before 34 weeks of gestation.
A sample size of 254 pregnant women will be included at 29 participating hospitals in order to demonstrate
noninferiority of placing a pessary versus vaginal progesterone. The first patient was randomized in August 2012,
and recruitment of study subjects will continue until the end of December 2015.
Discussion: This trial assesses the comparative efficacy and safety between two accepted treatments, cervical
pessary versus vaginal progesterone, and it will provide evidence in order to establish clinical recommendations.
Trial registration: EU Clinical Trials Register EudraCT2012-000241-13 (Date of registration: 16 January 2012);
ClinicalTrials.gov Identifier NCT01643980 (Date of registration: 12 June 2012).
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Background
Preterm birth, defined as birth before 37 weeks of gesta-
tion, is the second most frequent direct cause of infant
death in children younger than 5 years old [1–4]. Pre-
term birth is considered a major problem in modern
Obstetrics, and it is the leading cause of perinatal mor-
bidity and mortality in developed countries [5]. It is also
associated with an important economic burden [6, 7].
Despite significant medical advances, the rate of prema-
turity has not declined over the past 40 years; rather, it
has continued to rise. An increase in maternal age and
underlying maternal health problems, such as diabetes
and hypertensive disorders or iatrogenic factors like
greater use of infertility treatments, which lead to in-
creased rates of multiple pregnancies and changes in ob-
stetric practices (such as more caesarean births before
term) [8] have been identified as different reasons that
explain this phenomenon. The prevalence of preterm
births is about 12 to 13 % in the United States of
America and 5 to 9 % in the European Union and other
developed countries [5]. Although all deliveries before
37 weeks of gestation are considered preterm, the high-
est proportion of complications and neonatal death
occur in those born at less than 34 weeks.
In order to reach an effective decrease of prematurity,
two premises are necessary: to identify pregnant women
who are at risk and to dispose of measures that serve to
extend pregnancy, thus avoiding the prematurity. Some
published papers describe sonographic measurement of
the cervix at the 16th week as a method of screening to
detect women at risk of spontaneous preterm delivery
[3, 9–11]. In 1996 [1], Iams et al. demonstrated that the
risk of preterm delivery is inversely proportional to the
length of the cervix on transvaginal ultrasonography
(US) between 24 and 28 weeks of gestation in a nonse-
lected population in the United States of America.
After this publication [1], several studies have shown
that the risk of preterm birth was inversely correlated to
the length of the cervix as measured by transvaginal
ultrasound [2, 3, 9, 12, 13], which has been confirmed in
a recent meta-analysis [14].
Therefore, considering that the risk of prematurity is
inversely proportional to cervical length, cervical meas-
urement constitutes a method of screening for use in
pregnant women who are asymptomatic before 24 weeks
[15–17]. For decades, different types of therapeutic
intervention have been explored in order to decrease
preterm births, including primary prevention measures
(all pregnant women), secondary prevention measures
(only in women at risk) or tertiary prevention measures
(initiated after the delivery process has started) [18]. A
recent review concluded that there was insufficient
evidence to provide sound recommendations for clin-
ical practice in approximately half of the evaluated
interventions [19]. Nevertheless, according to several
trials and systematic reviews, two strategies, vaginal
progesterone [20–28] and silicon cervical pessary
[29–32], have been shown to be effective at decreas-
ing the rate of spontaneous delivery before 34 weeks
of gestation in at-risk women who have a short
cervix.
Progesterone is a key hormone during gestation that
has uterus-relaxing effects. Low levels of progesterone
are associated with a high grade of cervix maturation
and, consequently, a shorter cervical length and a higher
risk of spontaneous delivery. The administration of pro-
gesterone supplements decreases preterm delivery in
women with a short cervix [20–23] and in pregnant
women with a history of preterm births [25, 26].
In March 2012, Romero et al. published a meta-
analysis [27], which explored whether the use of vaginal
progesterone in asymptomatic women whose ultrasound
showed a short cervix (under 25 mm) in the second tri-
mester reduced the risk of preterm birth and improved
neonatal morbidity and mortality.
Five relevant clinical trials, which included a total
of 775 women and 827 infants, were analyzed. The
results showed that treatment with vaginal progester-
one was associated with a significant reduction in the
preterm birth rate before 33 weeks (12.4 % versus
22.0 %; relative risk (RR) 0.58; 95 % confidence inter-
val (CI), 0.42 to 0.80), <35 weeks (RR, 0.69; 95 % CI,
0.55 to 0.88), and <28 weeks (RR, 0.50; 95 % CI, 0.30
to 0.81); respiratory distress syndrome (RR, 0.48; 95%
CI, 0.30 to 0.76); composite neonatal morbidity and
mortality (RR, 0.57; 95 % CI, 0.40 to 0.81); birth
weight <1500 g (RR, 0.55; 95 % CI, 0.38 to 0.80);
admission to neonatal intensive care unit (RR, 0.75;
95 % CI, 0.59 to 0.94); and requirement for mechan-
ical ventilation (RR, 0.66; 95 % CI, 0.44 to 0.98).
There were no significant differences in the rate of
adverse maternal events or congenital anomalies be-
tween the vaginal progesterone and placebo groups.
The authors concluded that the data provides suffi-
cient evidence about the benefit of vaginal progester-
one to prevent the preterm birth in women with a
sonographic short cervix. They recommend measuring
cervical length using transvaginal sonogram at 19 to
24 weeks of gestation.
Although cervical pessaries were introduced for
management of cervical incompetence [33–35] at the
end of the 1950s, a very limited number of papers re-
garding the use of pessaries in pregnant women have
been found. In a case control study, Arabin et al. [29]
observed that the prematurity rate significantly de-
creased in singleton and twin pregnancies in women
with a short cervix in comparison with the controls
when pessaries were used.
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The first randomized study using a pessary (PECEP
trial) was published in 2012 [30]. A total of 385
pregnant women with singleton pregnancies and a
cervix length of ≤25 mm detected through vaginal
ultrasonography at 18 to 22 weeks of gestation were
randomized (1:1) to cervical pessary or expectant
management. A significant reduction (76 %) in spon-
taneous deliveries before 34 weeks was found in the
pessary group (6.3 % versus 26.8 %; odds ratio 0.18,
95 % CI 0.08 to 0.37; P <0.0001). In addition, a de-
crease in low-weight neonates (<2500 g) was de-
tected (6.3 % versus 29.5 %; odds ratio 0.23, 95 % CI
0.12 to 0.43; P <0.0001). After the PECEP publica-
tion, it was suggested [31] that more studies are
needed in different settings to confirm the results of
this single trial.
Finally, regarding safety, it is worth highlighting
that natural, micronized vaginal progesterone is a
medicine that can be administered either orally or
vaginally. There are no described adverse reactions
in the product monograph when it is administered
vaginally. Some women have reported a slight in-
crease in vaginal discharge [36]. Cervical pessary
can produce an increase in vaginal discharge, but
without an increase in bacterial vaginosis or cor-
ioamnionitis in pregnant women. Although slight
discomfort can sometimes occur during pessary
placement, most patients note that the discomfort is
acceptable [30].
Because of the published data, ultrasound measure-
ment of the cervix is being progressively incorporated
into clinical practice and either pessary or progester-
one is increasingly being used in women with a short
cervix. However, there is a “therapeutic hole” and nei-
ther of the two strategies is approved for this indica-
tion. In order to clear up any doubts about the
potential benefits of both treatments and to establish
clinical recommendations, comparative data are ne-
cessary. Alfirevic et al. [37] compared three different
cohorts using cervical pessary, vaginal progesterone or
cerclage for women with a singleton pregnancy and a
high risk of preterm birth due to a prior spontaneous
preterm birth before 34 weeks and a shortened cer-
vical length as detected by transvaginal ultrasound.
Their data suggests that the three treatments are a
reasonable option in this population and they con-
cluded that direct randomized comparisons of these
strategies are needed.
The main objective of the PESAPRO trial is to com-
pare the efficacy of two treatments, vaginal progesterone
and cervical pessary, in terms of decreasing the rate of
spontaneous preterm births before 34 weeks of gestation
in women with a short cervix, which has been detected
by transvaginal ultrasonography.
Methods/Design
PESAPRO is a noncommercial, national, multicenter,
randomized, open-label trial designed to compare the
effect on premature birth prevention of two currently ac-
cepted strategies: administration of progesterone (vaginally)
or the placement of vaginal pessaries in pregnant
women with a short cervix (≤25 mm) as diagnosed by
transvaginal ultrasonography (US) in the second tri-
mester morphology ultrasound.
The inclusion of a third arm with placebo control was
discussed in the original design because it would have
been a valuable tool from a methodological point of
view.- However, it was later discarded due to ethical and
feasibility issues after taking into consideration the most
recent publications.
Participating centers
Thirty-one hospitals are currently participating in the
PESAPRO trial. Fourteen center had initially been in-
vited to participate, and, later, 17 additional hospitals
were incorporated into the trial in a second phase.
All participating Obstetrics Units routinely perform
transvaginal ultrasonography in the second term as a
screening diagnosis method to detect women at risk of
preterm birth (listed in Appendix 1).
Study population and trial development
Pregnant women with a short cervix (≤25 mm) as
identified by routine transvaginal ultrasonography at
19 to 22 weeks of gestation are eligible to enroll. Be-
fore the evaluation, the woman should have an empty
bladder and be placed in the dorsal lithotomy pos-
ition. The vaginal probe should be placed in the an-
terior fornix without pressure. Initial orientation is
established by locating the sagittal view of the cervix.
The length of the endocervical canal should be
measured in a straight line from the internal to the
external cervix. The cervix is dynamic; therefore,
three measurements should be made over a 3-minute
period, and the shortest measurement reported for
clinical use [16, 38]. During this routine ultrasonog-
raphy in the second term, singleton-pregnancy women
with a short cervix (≤25 mm) are considered to par-
ticipate in the PESAPRO trial. Table 1 shows the in-
clusion and exclusion criteria. A member of the
research team informs the patient about the clinical
trial during this (second trimester ultrasound) visit or
at a different time, according to investigator criteria.
Once informed consent has been obtained and base-
line data has been collected (demographic, medical
and obstetric history, vaginal and endocervix samples
for culture), participants are individually randomized
to vaginal progesterone or pessary. Study participants
are evaluated every four weeks (±7 days) for a total
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of four visits; routine assessments (such as blood
pressure, and weight), cervicometry and fetal ultra-
sonography are performed during each visit to assess
adverse events and compliance with the study medi-
cation (in the progesterone group). Women are asked
to return unused study medication from the previous
4 weeks and compliance is determined on the basis
of the amount of the study drug that is unused. Study
treatments continue until the third term (37 to 37 + 4
weeks), when the obstetrician removes the pessary,
collects all the leftover medication, or until delivery,
whichever occurs first.
Any patients who develop preterm labor during the
study are treated according to the standard practice
of the participating institution. The study treatments
continue during hospitalization until the moment at
which delivery is unavoidable or until completion of
gestation is indicated. One additional assessment
(medical record review or phone call) is performed 4
to 6 weeks after delivery in order to collect full data.
See Table 2 for the detailed schedule of enrollment
and assessments.
Randomization
Consecutive eligible patients are randomly allocated in a
1:1 ratio to one of the two treatment groups: vaginal
progesterone or cervical pessary. The randomization se-
quence is computer generated (by EpiDat program). It is
protected and it is managed exclusively by the Clinical
Pharmacology Unit at University Hospital Puerta de
Hierro - Majadahonda, which has no role in recruitment.
The investigators receive the patient’s identification (ID)
number and the assigned treatment by a central phone
call, after having been informed that a new patient has en-
tered into the trial. An auditable registry of the date and
time of inclusion, patient ID number and treatment as-
signment is stored in the sponsor’s records.
Study interventions
Two accepted treatments in the management of preterm
birth risk are being assessed in the PESAPRO trial, al-
though neither of them is approved for use in this condi-
tion. For statistical purposes, we consider the pessaries
to be the experimental group and progesterone to be the
reference (or comparator) group. Patients who are
assigned to the comparator group receive 200 mg of mi-
cronized progesterone per day by vaginal route; women
self-administer the medicine once daily, preferably be-
fore going to bed.
The cervical pessary used in this study is a
perforated-cerclage type pessary, a hypoallergenic
silicon medical device certified by European Con-
formity, size 65/25/32 (65 mm lower larger diameter,
25 mm height and 32 mm upper smaller diameter).
The pessary is disposed of (and removed) by quali-
fied personnel (Obstetrician) at the clinic. Both treat-
ments are withdrawn between the 37th week and
37 week + 4.
Treatment registry
During the trial, both treatments are being properly regis-
tered. The commercial progesterone used (PROGGEFFIK™)
Table 1 Inclusion and exclusion criteria for PESAPRO
Inclusion criteria Exclusion criteria
• Women older than 18 years old • Major fetal and/ or uterine abnormalities
• Pregnant women with a short cervix (<25 mm) identified by the
use of routine transvaginal ultrasonography at 19 to 22 weeks
of gestation
• Placenta previa during current pregnancy
• Gestational age at randomization between 20 weeks + 1 and
23 weeks+6
• Vaginal bleeding or ruptured membranes in the moment of randomization
• Single pregnancy • Cervical cerclage in situ
• Women sign informed consent according to the GCP and local
legislation
• History of cone biopsy
• History of three or more premature labor
• Allergic to peanut
• Contraindication for progesterone usage
• Active treatment with progesterone at randomization
• If in an investigator’s opinion, there are findings on physical examination, abnormalities
in the results of clinical analyzes or other medical factors, social or psychosocial that
could negatively influence
• Women unable to give the informed consent
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is re-labelled in the Clinical Trials Pharmacy Unit of the
University Hospital Puerta de Hierro - Majadahonda and
then distributed to all participating centers. The
label includes the following data: trial code, sponsor
name, investigational product, batch number, expir-
ation date and the trial subject identification num-
ber. Regarding the pessary, the batch number and
the expiration date also are being registered.
Study outcomes
The primary outcome measure is the proportion of
spontaneous preterm birth before 34 weeks of gestation.
The secondary outcomes are the following: proportion
of spontaneous preterm birth before the 37th and 28th
weeks, the rate of premature rupture of membranes be-
fore 34 weeks, the neonate’s weight at birth, the rate of
fetal intrauterine mortality during the treatment period,
the rate of neonatal morbidity and mortality, the need
for hospitalization and tocolysis treatment, the rate of
chorioamnionitis during the third term, symptomatic va-
ginal infections during the treatment period and the pro-
portion of participants with adverse events.
Statistical analysis
A sample size of 254 women (127 women per arm) was
predefined to show the noninferiority of the experimental
group (pessary) versus the reference group (progester-
one), assuming a proportion of preterm birth (before
34 weeks) of 6 % and 12.4 %, respectively, with a
noninferiority margin of 4 %, a 2.5 % one-sided alpha
level, a statistical power of 80 % and a drop-out rate
of 5 %.
Statistical analysis will be based on the intention-
to-treat principle and a sensitivity analysis using the
per-protocol subset for the main outcome will be
used for sensitivity purposes. The noninferiority hy-
pothesis will be tested by estimating treatment rate
differences against the noninferiority margin. The
survival function and the median (95 % confidence
interval (CI)) time to delivery will be estimated by
means of the Kaplan-Meier method and treatment
effects will be compared using the log-rank test and
hazard ratios (HR) (95% CI) will be taken from the
Cox model. The rest of the variables will be analyzed
using the Fisher’s exact test to compare categorical
data, the t-test for continuous variables and the
Mann- Whitney test for ordinal and non-normally
distributed variables.
The analysis will be performed using SAS v9.2, or a
newer version, software (SAS Institute Inc., Cary, NC,
USA), and the level of significance will be set at 5 %
(two-sided).
Organization of the trial
PESAPRO is a noncommercial trial organized by the
Obstetrics and Gynecology Department and the Clinical
Table 2 Schedule of PESAPRO study’s visit
Visit 1 (Routine
control 2 term)a
Inform
Visit
Visit 0 basal
(20 weeks + 1
to 23 weeks + 6)
Visit 1
(V0 + 4 weeks)
Visit 2
(V1 + 4 weeks)
Visit 3
(V2 + 4 weeks)
Visit 4 (EOT)
(37 weeks to
37 weeks + 4)
Post-delivery
visit (4 to 6 weeks
post-delivery)
Eligibility criteria √ √
Informed consent √
Randomization and
start of treatment
√
Blood pressure/
weight
√ √ √ √ √
Vaginal culture √
Manual vaginal
exam
√ √
Cervicometry √ √ √ √ √ √
Follow-up
Questionnaire
√ √ √ √
Basic fetal US √ √ √ √
End of treatment
(EOT)
√
Review maternal
medical history
√ √
Review neonate
medical history
√
aThis visit is a routine (“standard of care”) visit in the control of pregnancy. Patients with a short cervix are invited to an extra visit (for information) before being
enrolled in the study
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Pharmacology Unit of the University Hospital Puerta de
Hierro - Majadahonda. The sponsor role is taken by C.
Martinez-Payo. The medical coordinator of the trial is S.
Cruz Melguizo. The Clinical Pharmacology Unit oversees
the methodological and organizational aspects of the
study. Since 2014, the study has been receiving support
from the Spanish Clinical Research network (SCReN) for
regulatory and administrative support, monitoring, data
management and pharmacovigilance. The PESAPRO
study group comprised of all clinical investigators at
the participating centers and the collaborators from
the Clinical Pharmacology Unit.
Funding/Support
The study is fully funded with public funds obtained in
competitive calls: grant PT13/0002/0005 (SCReN-Spanish
Clinical Research Network) from the National R+D+I
2013-2016 Plan of the Institute of Health Carlos III (AES
2013), grant EC11/086 of the Ministry of Health Call for
Independent Clinical Research in year 2011, and grant
PI12/02240 from the Institute of Health Carlos III, ISCIII,
from the National I+D+I 2008-2011 Plan and co-financed
by FEDER funds.
Coordination and conduct of the trial
The study is coordinated by the Obstetrics and
Gynecology Unit and the Clinical Pharmacology Unit
(Appendix 2). Three investigator meetings have been held
in order to review the study protocol and data collection
in the electronic case report form (eCRF). Additionally,
after the necessary approvals were obtained, a meeting
was held in each hospital before the start of patient re-
cruitment procedures. All documents required for the
study are available at each participating site. The eCRF is a
secure, interactive, web-response system available at each
study center, provided and managed by the Biostatistics
and Data Management Core Facility of Institut d’investi-
gacions Biomèdiques August Pi i Sunyer (IDIBAPS) -
Hospital Clínic, Barcelona.
In each participating Obstetrics Unit, the physicians
and research personnel (research nurse or assistant) are
in charge of patient screening and inclusion, ensuring
compliance with the study protocol and collecting the
study data in the eCRFs. The trial is being monitored by
an independent monitor. The monitor regularly reviews
the eCRFs, ensuring compliance with the trial protocol,
data completeness and data accuracy. All adverse events
and serious adverse events are being recorded according
to standard procedures.
Ethical considerations
The trial has been registered at European Clinical
Trial Database (EUDRACT2012-000241-13) and at
ClinicalTrials.gov (NCT01643980). The study is being
conducted in accordance with Good Clinical Practice
guidelines, the guiding principles of the Declaration of
Helsinki, and applicable local regulations. The study
was approved by the Spanish National Competent Au-
thority (AEMPS) and by the Research Ethics Commit-
tees of the participating centers (listed in Appendix 3).
Any relevant protocol amendments will be submitted
to the competent Ethics Committee for review and will
be updated in the trial registries. Participants are pro-
vided with information sheets and written informed
consent is obtained prior to recruitment and baseline
assessment.
A specific insurance policy has been contracted to
cover compensations to patients in the event of injuries,
in compliance with the requirements of Spanish law re-
garding clinical trials.
Although a third control arm with placebo is very
valuable from a methodological point of view in a
noninferiority comparative trial, it was discarded in
our trial. The main reason was related to the fact
that most participant hospitals were already treating
these women with a short cervix (either with a pes-
sary or with progesterone) as a measure to decrease
the risk of preterm birth, based on recent publica-
tions. Although confirming data with regards to the
superiority of both treatments versus placebo would
have been highly valuable, it was considered ethically
questionable.
Discussion
Preterm birth is a major public health problem with a
relevant neonatal morbimortality. It has been established
that a short cervix (≤25 mm) diagnosed by transvaginal
ultrasonography in the second trimester constitutes an
important risk factor of preterm delivery [1, 9, 11, 39].
Although several therapeutic strategies (vaginal proges-
terone, cervical pessary and cerclage) have been used in
these women showing a potential benefit, they have
never been compared to one another in randomized tri-
als. This study will assess the comparative efficacy of
two of these three treatments (vaginal progesterone ver-
sus pessary). It is possible that the results of this study
will contribute to the establishment of clinical recom-
mendations regarding the use of both treatments in the
prevention of preterm delivery in women with a short
cervix.
Trial status
Patient inclusion to the PESAPRO trial began in
September 2012. Enrollment is ongoing. The study is be-
ing conducted at 29 investigational sites. As of May 2015,
190 patients had been included in the study. Patient
recruitment is expected to end in July 2015.
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Appendix 1
Appendix 2
Steering committee
Sara Cruz Melguizo, Cristina Martínez-Payo, Luis San
Frutos, Francisco López Sánchez, Cristina Avendaño
Solá, Belén Ruiz Antorán, and Lourdes Cabrera García.
Data safety monitoring committee
– Dra. Caridad Pontes: Consultant Physician at
Hospital de Sabadell.
– Dr. José Ríos: Statistician Coordinator of the
Platform of Biostatistics and data Management
core and facilityb at the IDIBAPS (Hospital
Clinic Barcelona).
– Dr. Tirso Pérez: Head of Gynecology at
Hospital Universitario Puerta de Hierro
Majadahonda.
Table 3 PESAPRO trial sites and principal investigators
Site ID Trial sites Principal investigators
1 Hospital Puerta de Hierro Majadahonda Dra. Cristina Martínez Payo
Dra. Sara Cruz Melguizo
2 Hospital Príncipe de Asturias Dra. Estefanía Cordero
3 Hospital de Alcorcón Dr. Begoña Adiego Burgos
4 Hospital General Yagüe Dr. Javier Martínez Guisasola
5 Hospital de Getafe Dr. Luis Martínez Cortés
6 Hospital de León Dr. Celso García González
7 Hospital Río Hortega Dr. Gonzalo Quesada Segura
8 Hospital Ramón y Cajal Dr. Leopoldo Abarca
9 Hospital Miguel Servet Dr. Ricardo Savirón
11 Hospital Infanta Elena Dra. Esther Pérez Carbajo
12 Hospital InfantaSofía Dr. José Alberto Rodríguez León
13 Hospital La Paz Dr. José Luis Bartha
14 Hospital de Fuenlabrada Dra. MaríaTeulón
16 Hospital Universitario Rey Juan Carlos I Dra. Rosa Nogales
17 Hospital UniversitarioQuiron Dexeus Dr. Rodríguez
18 Hospital UniversitarioSevero Ochoa Dra. Gregoria Alonso
19 Hospital Clínico Universitario de Valladolid Dra. Cristina Álvarez Colomo
20 Hospital General Universitario de Ciudad Real Dra. M Ángeles Anaya Baz
21 Hospital Quirón Málaga Dr. Daniel Abehsera Davó
22 Hospital Universitario de Guadalajara Dra. Maria Jesús Cancelo
23 Hospital Sanitas la Zarzuela Dra. Elisa Maria Díaz De Teran
24 Hospital d´Igualada Dr. Joan Carles Mateu Pruñunosa
25 Hospital Madrid UniversitarioMonteprincipe Dra. Gloria Gálvez
26 Hospital Universitario Reina Sofía Dr. Antonio de la Torre
27 Hospital Palamos (ComarcalBaixEmporda) Dr. José Manuel Marqueta Sánchez
28 Hospital Universitario San Juan de Alicante Dra. Rosa Bermejo
29 Hospital Universitario de Donostia Dra. Arantza Lekuona Artola
30 Hospital Sanitas La Moraleja Dr. Eduardo Cabrillo Rodríguez
31 Hospital Universitario de Móstoles Dra. Emilia de Dios
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Abbreviations
CI: confidence interval; CMH: Cochran-Mantel-Haenszel; eCRF: electronic
case report form; IDIBAPS: Institutd’investigacions Biomèdiques August Pi i
Sunyer; ITT: intention to treat; ISCIII: Institute of Health Carlos III; PP: per
protocol; RCT: randomized clinical trials; RR: relative risk; SCReN: Spanish
Clinical Research Network; US: ultrasonography; USA: United States of
America.
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20 Hospital General Universitario de Ciudad Real Dra. M Ángeles Anaya Baz CEIC H. Gral. U. de Ciudad Real
21 Hospital Quirón Málaga Dr. Daniel Abehsera Davó CEIC Andalucía
22 Hospital Universitario de Guadalajara Dra. Maria Jesús Cancelo CEIC H. Gral. U. de Guadalajara
23 Hospital Sanitas la Zarzuela Dra. Elisa Maria Díaz De Teran CEIC H.U. Puerta de Hierro-Majadahonda
24 Hospital d´Igualada Dr. Joan Carles Mateu Pruñunosa CEIC del Hospital Universitari Bellvitge
25 Hospital Madrid Universitario Monteprincipe Dra. Gloria Gálvez CEIC Hospital de Madrid
26 Hospital Universitario Reina Sofía Dr. Antonio de la Torre CEIC Andalucía
27 Hospital Palamos (Comarcal Baix Emporda) Dr. José Manuel Marqueta Sánchez CEIC Institut d.Assistencia Sanitaria de Girona
28 Hospital Universitario San Juan de Alicante Dra. Rosa Bermejo CEIC Hospital General Universitario San Juan de Alicante
29 Hospital Universitario de Donostia Dra. Arantza Lekuona Artola CEIC de Euskadi
30 Hospital Sanitas La Moraleja Dr. Eduardo Cabrillo Rodríguez CEIC H.U. La Paz
31 Hospital Universitario de Móstoles Dra. Emilia de Dios CEIC H Universitario de Móstoles
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